国产精品又长又粗又爽又黄的毛片, 国产AV无码专区亚洲AV毛片搜, 丰满人妻被猛烈进入中文字幕四川, 国产精品一区二区三区国产女人喷,亚洲国产欧美日韩图片在线人,潘娇娇337p人艺体艺术,成人免费无码大片a毛片古装,一本到高清视频免费,人妻在线视频免费看

400-885-9898
更新于 11月10日
智聯(lián)APPAPP
舉報(bào)

高級研究員Ⅱ-ADC技術(shù)研發(fā)(J17983)

2-2.6萬·16薪
  • 上海浦東新區(qū)
  • 3-5年
  • 博士
  • 全職
  • 招1人

職位描述

ADC偶聯(lián)
崗位職責(zé):
1.Build an innovative ADC technique platform, explore the development of site-specific conjugation techniques, investigate innovative technological pathways such as bispecific ADC and dual-payload ADC, and promote the upgrade of ADC technique platform.
2.Responsible for project initiation evaluation, risk assessment, technique evaluation, patent planning, analysis of competitor development progression, and other research and development decision-making tasks for ADC projects.
3.Responsible for the design, screening, and structure-activity relationship research of novel linker-payloads, as well as the conjugation, purification, and analytical characterization of preclinical ADCs.
4.Operation management of XDC laboratory, as well as management of external CRO/CDMO resources, evaluation of partner qualifications, and ensuring efficient project delivery.
任職要求:
Education: Ph.D. or Master with validated successful experience, major in pharmacy/ chemistry/ biology/…, interdisciplinary background is preferred.
Experience: More than 3 years in ADC technology R&D
Skills and Competencies:
1.Proficient in antibody conjugation techniques, especially site-specific conjugation techniques, with experience in linker/payload design, bispecific ADC, and dual payload ADC development are preferred.
2.Continuously focusing on cutting-edge techniques in the industry, able to propose differentiated innovative research plans with feasibility for execution.
3.Familiar with the development process of ADCs/biologics, having knowledge of IND/BLA regulations in NMPA, FDA and EMA, as well as GMP requirements is preferred, experienced in managing CRO/CDMO collaborations.
4.Experienced in team leadership, strong communication skills, proficient in cross-departmental collaboration and resource integration.

工作地點(diǎn)

浦東新區(qū)上海復(fù)星健康科技(集團(tuán))有限公司1號樓8樓

職位發(fā)布者

孫女士/招聘主管

三日內(nèi)活躍
立即溝通
公司Logo上海復(fù)宏漢霖生物技術(shù)股份有限公司
復(fù)宏漢霖（2696.HK）是一家國際化的創(chuàng)新生物制藥公司，致力于為全球患者提供可負(fù)擔(dān)的高品質(zhì)生物藥，產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領(lǐng)域，已在中國上市5款產(chǎn)品，在國際上市1款產(chǎn)品，18項(xiàng)適應(yīng)癥獲批，3個(gè)上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來，復(fù)宏漢霖已建成一體化生物制藥平臺，高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運(yùn)營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心，按照國際藥品生產(chǎn)質(zhì)量管理規(guī)范（GMP）標(biāo)準(zhǔn)進(jìn)行生產(chǎn)和質(zhì)量管控，不斷夯實(shí)一體化綜合生產(chǎn)平臺，其中，上海徐匯基地已獲得中國和歐盟GMP認(rèn)證，松江基地（一）也已獲得中國GMP認(rèn)證。復(fù)宏漢霖前瞻性布局了一個(gè)多元化、高質(zhì)量的產(chǎn)品管線，涵蓋20多種創(chuàng)新單克隆抗體，并全面推進(jìn)基于自有抗PD-1單抗H藥漢斯?fàn)?的腫瘤免疫聯(lián)合療法。繼國內(nèi)首個(gè)生物類似藥漢利康?（利妥昔單抗）、中國首個(gè)自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?（曲妥珠單抗，歐洲商品名：Zercepac?，澳大利亞商品名：Tuzucip?和Trastucip?）、漢達(dá)遠(yuǎn)?（阿達(dá)木單抗）和漢貝泰?（貝伐珠單抗）相繼獲批上市，創(chuàng)新產(chǎn)品漢斯?fàn)?（斯魯利單抗）已獲批用于治療微衛(wèi)星高度不穩(wěn)定（MSI-H）實(shí)體瘤、鱗狀非小細(xì)胞肺癌和廣泛期小細(xì)胞肺癌，成為全球首個(gè)獲批一線治療小細(xì)胞肺癌的抗PD-1單抗，其食管鱗狀細(xì)胞癌適應(yīng)癥的上市注冊申請也正在審評中。公司亦同步就16個(gè)產(chǎn)品在全球范圍內(nèi)開展30多項(xiàng)臨床試驗(yàn)。
公司主頁